021-51111890
购物车（0）
sales@molnova.cn
LY2109761
CAS No. 700874-71-1
LY2109761 ( LY 2109761 | LY-2109761 )
产品货号. M15688 CAS No. 700874-71-1
一种有效的、选择性的、口服活性的 TGF-β RI/II 双重抑制剂，Ki 分别为 38/300 nM。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 2MG | ￥316 | 有现货 |
|
| 5MG | ￥518 | 有现货 |
|
| 10MG | ￥915 | 有现货 |
|
| 25MG | ￥1604 | 有现货 |
|
| 50MG | ￥2859 | 有现货 |
|
| 100MG | ￥4317 | 有现货 |
|
| 200MG | ￥6229 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称LY2109761
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述一种有效的、选择性的、口服活性的 TGF-β RI/II 双重抑制剂，Ki 分别为 38/300 nM。
-
产品描述A potent, selective and orally active TGF-β RI/II dual inhibitor with Ki of 38/300 nM, respectively; completely inhibits TGF-β-induced Sma2 phosphorylation on tumor cells or the liver microenviroment, inhibits the L3.6pl/GLT soft agar growth, suppresses both basal and TGF-β1-induced cell migration and invasion, and stimulates anoikis in vitro; significantly reduces the tumor burden as well as spontaneous abdominal metastases, and prolongs survival combined with gemicitabine in vivo model of pancreatic cancer.
-
体外实验——
-
体内实验——
-
同义词LY 2109761 | LY-2109761
-
通路TGF-beta/Smad
-
靶点TGFBR
-
受体TβRI|TβRII
-
研究领域Cancer
-
适应症——
化学信息
-
CAS Number700874-71-1
-
分子量441.5249
-
分子式C26H27N5O2
-
纯度>98% (HPLC)
-
溶解度10 mM in DMSO
-
SMILESN1(CCOC2=CC=C3C(C4=C(CCC5)N5N=C4C6=NC=CC=C6)=CC=NC3=C2)CCOCC1
-
化学全称Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[2-(4-morpholinyl)ethoxy]-
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Mazzocca A, et al. Hepatology. 2009 Oct;50(4):1140-51.
2. Zhang M, et al. Cancer Res, 2011, 71(23), 7155-7167.
3. Melisi D, et al. Mol Cancer Ther, 2008, 7(4), 829-840.
